JP2020505932A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505932A5 JP2020505932A5 JP2019542407A JP2019542407A JP2020505932A5 JP 2020505932 A5 JP2020505932 A5 JP 2020505932A5 JP 2019542407 A JP2019542407 A JP 2019542407A JP 2019542407 A JP2019542407 A JP 2019542407A JP 2020505932 A5 JP2020505932 A5 JP 2020505932A5
- Authority
- JP
- Japan
- Prior art keywords
- immune effector
- effector cell
- chimeric antigen
- antigen receptor
- cytoplasmic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762456649P | 2017-02-08 | 2017-02-08 | |
| US62/456,649 | 2017-02-08 | ||
| US201762457124P | 2017-02-09 | 2017-02-09 | |
| US62/457,124 | 2017-02-09 | ||
| PCT/US2018/017464 WO2018148440A1 (en) | 2017-02-08 | 2018-02-08 | Regulating chimeric antigen receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020505932A JP2020505932A (ja) | 2020-02-27 |
| JP2020505932A5 true JP2020505932A5 (OSRAM) | 2021-03-25 |
| JP7227912B2 JP7227912B2 (ja) | 2023-02-24 |
Family
ID=63107041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542407A Active JP7227912B2 (ja) | 2017-02-08 | 2018-02-08 | キメラ抗原受容体の調節 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11311609B2 (OSRAM) |
| EP (2) | EP3580212A4 (OSRAM) |
| JP (1) | JP7227912B2 (OSRAM) |
| CN (1) | CN111386263A (OSRAM) |
| AU (1) | AU2018219289A1 (OSRAM) |
| CA (1) | CA3053006C (OSRAM) |
| WO (1) | WO2018148440A1 (OSRAM) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102455171B1 (ko) | 2013-12-18 | 2022-10-14 | 더 스크립스 리서치 인스티튜트 | 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물 |
| AU2016301196B2 (en) * | 2015-08-06 | 2022-09-08 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| EP3559006A4 (en) | 2016-12-23 | 2021-03-03 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES |
| EP3558994A4 (en) | 2016-12-23 | 2021-05-12 | Arvinas Operations, Inc. | COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FAST ACCELERATED FIBROSARCOMA POLYPEPTIDES |
| RU2019121527A (ru) | 2016-12-23 | 2021-01-15 | Эрвинэс Оперейшнс, Инк. | Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения |
| MX2019008934A (es) | 2017-01-26 | 2019-11-05 | Arvinas Operations Inc | Moduladores de la proteolisis del receptor de estrogeno y métodos asociados de uso,. |
| US12023385B2 (en) * | 2017-02-08 | 2024-07-02 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation with heterobifunctional compounds |
| US11786551B2 (en) | 2017-09-26 | 2023-10-17 | The Trustees Of The University Of Pennsylvania | Methods for treating heart disease via redirected T cell immunotherapies |
| KR20200086278A (ko) | 2017-10-18 | 2020-07-16 | 노파르티스 아게 | 선택적 단백질 분해를 위한 조성물 및 방법 |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| CN119569702A (zh) | 2018-04-04 | 2025-03-07 | 阿尔维纳斯运营股份有限公司 | 蛋白水解调节剂及相关使用方法 |
| US11707452B2 (en) | 2018-08-20 | 2023-07-25 | Arvinas Operations, Inc. | Modulators of alpha-synuclein proteolysis and associated methods of use |
| GB201814203D0 (en) * | 2018-08-31 | 2018-10-17 | King S College London | Engineered regulatory t cell |
| EP3846800A4 (en) | 2018-09-04 | 2022-08-24 | C4 Therapeutics, Inc. | Compounds for the degradation of brd9 or mth1 |
| CA3109617A1 (en) * | 2018-09-27 | 2020-04-02 | Dana-Farber Cancer Institute, Inc. | Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use |
| WO2020077278A1 (en) * | 2018-10-12 | 2020-04-16 | The Scripps Research Institute | Compounds and methods for dcaf-mediated protein degradation |
| GB201816839D0 (en) * | 2018-10-16 | 2018-11-28 | Glaxosmithkline Ip Dev Ltd | Novel control switch |
| EP3866801A4 (en) * | 2018-10-16 | 2022-11-09 | Dana-Farber Cancer Institute, Inc. | DEGRADER OF WILD-TYPE AND MUTANT FORMS OF LRRK2 |
| EP3873539A4 (en) * | 2018-10-31 | 2023-01-18 | The Children's Hospital of Philadelphia | LYMPH-BASED T-CELLS FOR DIAGNOSTIC AND THERAPEUTIC USE |
| CN109293631B (zh) * | 2018-11-30 | 2020-05-08 | 常州制药厂有限公司 | 3-氨基-n-(2，6-二氧代-3-哌啶基)-邻苯二甲酰亚胺化合物的制备方法 |
| EP3908291A4 (en) * | 2019-01-07 | 2023-01-11 | Dana-Farber Cancer Institute, Inc. | SMALL MOLECULAR DEGRADERS OF FKBP12 VIA RECRUITMENT OF THE VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) AND USE IN DTAG SYSTEMS |
| US12419913B2 (en) | 2019-02-08 | 2025-09-23 | Dna Twopointo, Inc. | Modification of CAR-T cells |
| AU2020218546A1 (en) * | 2019-02-08 | 2021-09-09 | Dna Twopointo Inc. | Transposon-based modifications of immune cells |
| WO2020190771A1 (en) * | 2019-03-15 | 2020-09-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
| US20230093099A1 (en) * | 2019-04-02 | 2023-03-23 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| WO2020206608A1 (en) | 2019-04-09 | 2020-10-15 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Methods and compositions for targeted protein degradation |
| MA55628A (fr) | 2019-04-12 | 2022-02-16 | C4 Therapeutics Inc | Agents de dégradation tricycliques d'ikaros et d'aiolos |
| EP3962480A4 (en) * | 2019-05-01 | 2023-06-07 | Nemucore Medical Innovations, Inc. | DEGRADATION OF AURORAKINASE (AURK) BY CONJUGATION OF AURK INHIBITORS WITH E3 LIGASE LIGAND |
| KR20220024098A (ko) * | 2019-06-19 | 2022-03-03 | 리본 테라퓨틱스 인코포레이티드 | 요법에 사용하기 위한 parp14의 표적화된 단백질 분해 |
| WO2021011913A1 (en) | 2019-07-17 | 2021-01-21 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| KR20220066312A (ko) | 2019-09-23 | 2022-05-24 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 섬유아세포 활성화 단백질 (fap)의 표적화에 의한 종양 조직 파괴 |
| KR20220066090A (ko) | 2019-09-23 | 2022-05-23 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 마우스 및 인간 섬유아세포 활성화 단백질(fap)과 교차 반응하는 개과 섬유아세포 활성화 단백질에 대한 모노클로날 항체 |
| US12310975B2 (en) | 2019-10-17 | 2025-05-27 | Arvinas Operations, Inc. | Modulators of BCL6 proteolysis and associated methods of use |
| ES2991652T3 (es) * | 2019-10-23 | 2024-12-04 | Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis | Polipéptido quimérico para regular las células inmunitarias |
| CA3163507A1 (en) | 2019-12-04 | 2021-06-10 | The Scripps Research Institute | Peptide conjugates and methods of use |
| EP4077680A4 (en) * | 2019-12-17 | 2024-01-10 | Orionis Biosciences, Inc. | DETECTION OF NEW DEGRADATION-RELATED INTERACTIONS |
| EP4681715A3 (en) | 2019-12-20 | 2026-01-28 | C4 Therapeutics, Inc. | Isoindolinone and indazole compounds for the degradation of egfr |
| MX2022008050A (es) * | 2020-01-16 | 2022-07-27 | Genmab As | Formulaciones de anticuerpos anti cumulo de diferenciacion 38 (cd38) y usos de las mismas. |
| CA3172720A1 (en) * | 2020-03-31 | 2021-10-07 | Nathan FISHKIN | Conjugates |
| AU2021312871A1 (en) * | 2020-07-21 | 2023-02-09 | Allogene Therapeutics, Inc. | Chimeric antigen receptors with enhanced signaling and activities and uses thereof |
| EP4204418A1 (en) | 2020-08-28 | 2023-07-05 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| CN112194726B (zh) * | 2020-09-02 | 2023-06-23 | 沣潮医药科技（上海）有限公司 | 用于病理性蛋白聚集物清除的嵌合抗原受体及其应用 |
| CN116209439A (zh) | 2020-09-23 | 2023-06-02 | 圣裘德儿童研究医院有限公司 | 作为cereblon蛋白调节剂的取代的N-(2-(2,6-二氧代哌啶-3-基)-1,3-二氧代异吲哚啉-5-基)芳基磺酰胺类似物 |
| CN116323570B (zh) * | 2020-09-30 | 2025-02-11 | 上海睿跃生物科技有限公司 | 治疗疾病的化合物和方法 |
| US20240124460A1 (en) * | 2020-10-14 | 2024-04-18 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for targeted protein degradation |
| US20240124465A1 (en) * | 2020-12-18 | 2024-04-18 | St. Jude Children's Research Hospital | Molecules and methods related to treatment of disorders associated with jak-2 signaling dysfunction |
| CN113234162B (zh) * | 2020-12-24 | 2022-05-13 | 四川大学华西医院 | 一种靶向cd133的嵌合抗原受体t细胞 |
| CN113087798B (zh) * | 2020-12-31 | 2022-05-24 | 北京艺妙神州医药科技有限公司 | 一种抗bcma的抗体及其应用 |
| JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス， インコーポレイテッド | イソインドリノン化合物 |
| CA3214806A1 (en) | 2021-04-16 | 2022-10-20 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
| AU2022262046A1 (en) * | 2021-04-19 | 2023-11-02 | Nanjing Legend Biotech Co., Ltd. | Chimeric cytokine receptors and uses thereof in cellular therapies |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| IL309067A (en) | 2021-06-09 | 2024-02-01 | Scripps Research Inst | Long-acting dual gip/glp-1 peptide conjugates and methods of use |
| US20250129047A1 (en) | 2021-07-04 | 2025-04-24 | Newave Pharmaceutical Inc. | Isoquinoline derivatives as mutant egfr modulators and uses thereof |
| CN115677667B (zh) * | 2021-07-30 | 2024-11-15 | 海创药业股份有限公司 | 一种双功能嵌合体杂环化合物及其作为雄激素受体降解剂的用途 |
| US20240424136A1 (en) * | 2021-10-18 | 2024-12-26 | Obsidian Therapeutics, Inc. | Compositions and systems for regulation of function/abundance and delivery of polypeptide payloads |
| EP4424714A4 (en) * | 2021-10-29 | 2025-10-15 | Shanghai Sinobay Biotechnology Co Ltd | Condition-Controlled Splicable Chimeric Antigen Receptor Molecule and Its Use |
| EP4176895A1 (en) * | 2021-11-08 | 2023-05-10 | AvenCell Europe GmbH | Targeting modules against il13ra2 or her2 for use in combination with a chimeric antigen receptor |
| CN114874132B (zh) * | 2022-05-24 | 2023-06-06 | 无锡捷化医药科技有限公司 | 一种重组人受体蛋白fkbp12配体的制备方法 |
| WO2024015618A2 (en) * | 2022-07-15 | 2024-01-18 | St. Jude Children's Research Hospital, Inc. | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione/2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione analogs as modulators of cereblon protein |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| CN116554353B (zh) * | 2023-04-28 | 2024-05-03 | 北京奇迈永华生物科技有限公司 | 一种假病毒高效感染人nk细胞及其他免疫细胞的方法 |
| AU2024310341A1 (en) | 2023-06-30 | 2026-02-12 | Merck Patent Gmbh | Heterobifunctional compounds for the degradation of kras protein |
| EP4735438A2 (en) | 2023-06-30 | 2026-05-06 | Merck Patent GmbH | Heterobifunctional compounds for the degradation of kras |
| KR20250017174A (ko) * | 2023-07-25 | 2025-02-04 | 한국화학연구원 | 면역세포의 조절 시스템 |
| WO2025122943A1 (en) * | 2023-12-08 | 2025-06-12 | Obsidian Therapeutics, Inc. | Compositions and methods for enhanced payload regulation using nuclear factor of activated t cells (nfat) response elements |
| CN119410598A (zh) * | 2024-09-27 | 2025-02-11 | 武汉大学 | 一种靶标识别系统及其应用 |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4694778A (en) | 1984-05-04 | 1987-09-22 | Anicon, Inc. | Chemical vapor deposition wafer boat |
| US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US5763590A (en) | 1991-10-11 | 1998-06-09 | Vertex Pharmaceuticals, Inc. | Isolation of an Mr 52,000 FK506 binding protein and molecular cloning of a corresponding human cDNA |
| US5686278A (en) | 1994-03-25 | 1997-11-11 | Indiana University Foundation | Methods for enhanced retrovirus-mediated gene transfer |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| FR2741066B1 (fr) | 1995-11-14 | 1997-12-12 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2743365A1 (fr) | 1996-01-10 | 1997-07-11 | Rhone Poulenc Rorer Sa | Derives de 5h,10h-imidazo(1,2-a)indolo(3,2-e)pyrazine-4-one, leur preparation et les medicaments les contenant |
| DE19605548A1 (de) | 1996-02-15 | 1997-09-04 | Boehringer Ingelheim Int | Zusammensetzung für die Transfektion höherer eukaryotischer Zellen |
| DE19607686A1 (de) | 1996-02-29 | 1997-09-04 | Chemicon Lab Gmbh | Neue metabolisierbare Lipopolyamine, deren Darstellung und Anwendung |
| WO2000001836A1 (en) | 1998-07-01 | 2000-01-13 | Takara Shuzo Co., Ltd. | Gene transfer methods |
| CA2343917A1 (en) | 1998-10-19 | 2000-04-27 | Ariad Gene Therapeutics, Inc. | Materials and methods involving conditional retention domains |
| US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| BR0108545A (pt) | 2000-02-24 | 2004-06-29 | Xcyte Therapies Inc | Estimulação e concentração simultâneas das células |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| CA2407945A1 (en) | 2000-05-04 | 2001-11-08 | Mount Sinai Hospital | Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US7208157B2 (en) | 2000-09-08 | 2007-04-24 | California Institute Of Technology | Proteolysis targeting chimeric pharmaceutical |
| EP1322750A4 (en) | 2000-09-08 | 2004-09-29 | California Inst Of Techn | PROTEOLYSIS TARGET DRUG TARGET MEDICINE |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| WO2005002526A2 (en) | 2003-07-01 | 2005-01-13 | President And Fellows Of Harvard College | Method and compositions for treatment of viral infections |
| US7371539B2 (en) | 2003-12-03 | 2008-05-13 | President And Fellows Of Harvard College | Targeted polypeptide degradation |
| CA2568344C (en) | 2004-05-27 | 2016-01-19 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
| HUE033581T2 (hu) | 2010-06-10 | 2017-12-28 | Seragon Pharmaceuticals Inc | Ösztrogén receptor modulátorok és alkalmazásaik |
| US8853423B2 (en) | 2010-06-17 | 2014-10-07 | Seragon Pharmaceuticals, Inc. | Indane estrogen receptor modulators and uses thereof |
| EP2614077B1 (en) | 2010-09-08 | 2016-08-17 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| AU2011338615B2 (en) | 2010-12-07 | 2017-07-27 | Yale University | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same |
| WO2013051718A1 (ja) | 2011-10-07 | 2013-04-11 | 国立大学法人三重大学 | キメラ抗原受容体 |
| SG11201403002RA (en) | 2011-12-14 | 2014-07-30 | Seragon Pharmaceuticals Inc | Fluorinated estrogen receptor modulators and uses thereof |
| EP2791128A4 (en) | 2011-12-16 | 2015-04-22 | Olema Pharmaceuticals Inc | NOVEL BENZOPYRAN COMPOUNDS, COMPOSITIONS AND USES THEREOF |
| JP2015508414A (ja) | 2012-01-12 | 2015-03-19 | イエール ユニバーシティ | Ｅ３ユビキチンリガーゼによる標的タンパク質および他のポリペプチドの分解増強のための化合物および方法 |
| US20150119435A1 (en) | 2012-05-11 | 2015-04-30 | Yale University | Compounds useful for promoting protein degradation and methods using same |
| LT3401400T (lt) | 2012-05-25 | 2019-06-10 | The Regents Of The University Of California | Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui |
| US9610332B2 (en) * | 2012-07-18 | 2017-04-04 | Massachusetts Institute Of Technology | Compositions and methods for modulating BRD4 bioactivity |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| SG10201912991WA (en) | 2012-12-17 | 2020-03-30 | Harvard College | Rna-guided human genome engineering |
| SI3300745T1 (sl) * | 2013-02-15 | 2020-01-31 | The Regents Of The University Of California | Himerni antigenski receptor in postopki njihove uporabe |
| SG11201507378UA (en) | 2013-03-14 | 2015-10-29 | Caribou Biosciences Inc | Compositions and methods of nucleic acid-targeting nucleic acids |
| US20140273230A1 (en) | 2013-03-15 | 2014-09-18 | Sigma-Aldrich Co., Llc | Crispr-based genome modification and regulation |
| US9234213B2 (en) | 2013-03-15 | 2016-01-12 | System Biosciences, Llc | Compositions and methods directed to CRISPR/Cas genomic engineering systems |
| US20140273235A1 (en) | 2013-03-15 | 2014-09-18 | Regents Of The University Of Minnesota | ENGINEERING PLANT GENOMES USING CRISPR/Cas SYSTEMS |
| PE20160874A1 (es) | 2013-05-28 | 2016-09-04 | Astrazeneca Ab | Compuestos quimicos |
| CN105793425B (zh) | 2013-06-17 | 2021-10-26 | 布罗德研究所有限公司 | 使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用 |
| WO2014203129A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Combinations of benzopyran compounds, compositions and uses thereof |
| MX2015016171A (es) | 2013-06-19 | 2016-08-08 | Seragon Pharmaceuticals Inc | Moduladores del receptor de estrogeno de azetidina y usos de los mismos. |
| WO2014203132A1 (en) | 2013-06-19 | 2014-12-24 | Olema Pharmaceuticals, Inc. | Substituted benzopyran compounds, compositions and uses thereof |
| WO2014205138A1 (en) | 2013-06-19 | 2014-12-24 | Seragon Pharmaceuticals, Inc. | Estrogen receptor modulator and uses thereof |
| US20160272635A1 (en) | 2013-07-23 | 2016-09-22 | Bayer Pharma Aktiengesellschaft | Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinases |
| AU2014298051B2 (en) | 2013-07-31 | 2018-11-15 | Zenith Epigenetics Ltd. | Novel quinazolinones as bromodomain inhibitors |
| US20150051208A1 (en) | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
| US9428513B2 (en) | 2013-11-07 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Triazolopyrazine |
| PT3071203T (pt) | 2013-11-18 | 2021-03-11 | Forma Therapeutics Inc | Composições de tetra-hidroquinolina como inibidores de bromodomínio bet |
| CA2930877A1 (en) | 2013-11-18 | 2015-05-21 | Crispr Therapeutics Ag | Crispr-cas system materials and methods |
| US9399640B2 (en) | 2013-11-26 | 2016-07-26 | Incyte Corporation | Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors |
| WO2015088643A1 (en) | 2013-12-11 | 2015-06-18 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| AU2014368892B2 (en) | 2013-12-20 | 2019-06-13 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
| JP6351306B2 (ja) | 2014-03-06 | 2018-07-04 | キヤノン株式会社 | 画像処理装置、画像処理装置の制御方法およびプログラム |
| US20160058872A1 (en) | 2014-04-14 | 2016-03-03 | Arvinas, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| CN119591582A (zh) | 2014-04-14 | 2025-03-11 | 阿尔维纳斯运营股份有限公司 | 基于酰亚胺的蛋白水解调节剂和相关使用方法 |
| EP3169702A4 (en) | 2014-07-14 | 2018-04-18 | The Regents of The University of California | A protein tagging system for in vivo single molecule imaging and control of gene transcription |
| US20160053272A1 (en) | 2014-07-18 | 2016-02-25 | Whitehead Institute For Biomedical Research | Methods Of Modifying A Sequence Using CRISPR |
| US10071164B2 (en) | 2014-08-11 | 2018-09-11 | Yale University | Estrogen-related receptor alpha based protac compounds and associated methods of use |
| EP3234144B1 (en) | 2014-12-15 | 2020-08-26 | Bellicum Pharmaceuticals, Inc. | Methods for controlled elimination of therapeutic cells |
| JP6815318B2 (ja) * | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| US9694084B2 (en) | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| MA41346A (fr) * | 2015-01-12 | 2017-11-21 | Juno Therapeutics Inc | Eléments régulateurs post-transcriptionnels d'hépatite modifiée |
| HK1245791A1 (zh) | 2015-01-20 | 2018-08-31 | 阿尔维纳斯运营股份有限公司 | 用於雄激素受体的靶向降解的化合物和方法 |
| US9777064B2 (en) | 2015-03-17 | 2017-10-03 | Chimera Bioengineering, Inc. | Smart CAR devices, DE CAR polypeptides, side CARs and uses thereof |
| JP7269731B2 (ja) | 2015-03-18 | 2023-05-09 | アルビナス・オペレーションズ・インコーポレイテッド | 標的タンパク質の分解向上のための化合物および方法 |
| MX2017012939A (es) * | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| CN107922508B (zh) | 2015-06-12 | 2021-06-04 | 艾希奥美公司 | 用于产生嵌合多肽的方法和组合物 |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CN108137507A (zh) | 2015-07-10 | 2018-06-08 | 阿尔维纳斯股份有限公司 | 基于mdm2的蛋白水解调节剂和相关的使用方法 |
| AU2016301196B2 (en) | 2015-08-06 | 2022-09-08 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| WO2018064589A1 (en) | 2016-09-29 | 2018-04-05 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation using a mutant e3 ubiquitin ligase |
-
2018
- 2018-02-08 EP EP18750939.3A patent/EP3580212A4/en not_active Withdrawn
- 2018-02-08 WO PCT/US2018/017464 patent/WO2018148440A1/en not_active Ceased
- 2018-02-08 US US16/483,204 patent/US11311609B2/en active Active
- 2018-02-08 EP EP22182901.3A patent/EP4119552A1/en active Pending
- 2018-02-08 JP JP2019542407A patent/JP7227912B2/ja active Active
- 2018-02-08 CA CA3053006A patent/CA3053006C/en active Active
- 2018-02-08 CN CN201880024542.9A patent/CN111386263A/zh active Pending
- 2018-02-08 AU AU2018219289A patent/AU2018219289A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018525006A5 (OSRAM) | ||
| JP2018508219A5 (OSRAM) | ||
| Müller et al. | A novel antibody–4-1BBL fusion protein for targeted costimulation in cancer immunotherapy | |
| JP2018520679A5 (OSRAM) | ||
| CA2246352A1 (en) | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith | |
| JP2021520853A5 (OSRAM) | ||
| Hornig et al. | Evaluating combinations of costimulatory antibody–ligand fusion proteins for targeted cancer immunotherapy | |
| JP2020521452A (ja) | 標的化免疫寛容 | |
| JP2020511136A5 (OSRAM) | ||
| JP2020509050A5 (OSRAM) | ||
| JP2020517295A5 (OSRAM) | ||
| JP2020513754A5 (OSRAM) | ||
| JP2017527275A5 (OSRAM) | ||
| JP2017537919A5 (OSRAM) | ||
| JP2020536531A5 (OSRAM) | ||
| JP2019501647A5 (OSRAM) | ||
| JP2022513116A5 (OSRAM) | ||
| Yu et al. | Identification of a ligand for glucocorticoid-induced tumor necrosis factor receptor constitutively expressed in dendritic cells | |
| JP2021500882A5 (OSRAM) | ||
| JP2017537629A5 (OSRAM) | ||
| Xia et al. | CD28: a new drug target for immune disease | |
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| JP2024536859A5 (OSRAM) | ||
| IL278245B1 (en) | Auto/Alloimmune Defense Receptors for Mucosal Targeting of Activated Pathogenic T and NK Cells | |
| Pawlak et al. | The soluble CTLA-4 receptor: a new marker in autoimmune diseases |